Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency

Nephrology Dialysis Transplantation

Volumn 12, Issue 9, 1997, Pages 1908-1915

  Samuelsson, O ^a,d   Mulec, H ^a   Knight Gibson, C ^b   Attman, P O ^a   Kron, B ^a   Larsson, R ^a   Weiss, L ^a   Wedel, H ^c   Alaupovic, P ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apolipoproteins; Chronic renal disease; Glomerular filtration rate; Lipids; Progression

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DYSLIPOPROTEINEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEINS; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0030865534     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.9.1908     Document Type: Article

References (49)

1. Attman P-O, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - relation to renal function and dialysis. Nephron 1991; 57: 401-410
2. Grützmacher P, März W, Peschke B, Gross W, Schoeppe W. Lipoproteins and apolipoproteins during the progression of chronic renal disease. Nephron 1988; 50: 103-111
3. Samuelsson O, Attman P-O, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P. Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency. Nephrol Dial Transplant 1994; 9: 1580-1585
4. Attman P-O, Samuelsson O, Alaupovic P. Lipid metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
5. Kim KE, Swartz C. Cardiovascular complications of end-stage renal disease. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney, Vol. 3. Uremic Syndrome. Boston, Little, Brown, 1988; 3093-3126
6. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-513
7. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-271
8. Moorhead JF, Chan MK, El Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 1: 1309-1311
9. Keane WF, O'Donnell MP, Kasiske BL, Schmitz PG. Lipids and the progression of renal disease. J Am Soc Nephrol 1990; 1: S690-S704
10. Mulec H, Johnson SA, Wiklund O, Björck S. Cholesterol: a renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993; 22: 196-201
11. Krolewski A, Warram JH, Chriestlieb AR. Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1995; 45 [Suppl.45]: S125-S131
12. Ravid M, Neuman L, Lishner M, Plasma lipids and the progression of nephropathy in diabetes mellitus type II. Effects of ACE inhibitors. Kidney Int 1995; 47: 907-910
13. Maschio G, Oldrizzi L, Rugio, DeBiase V, Loschiavo C. Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure. Kidney Int 1991; 395: S70-S72
14. Cappelli P, Evangelista M, Bononini M, Palmieri PF, Albertazzi A. Lipids in the progression of chronic renal failure. Nephron 1992; 62: 31-35
15. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman P-O. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993; 63: 279-285
16. Jagenburg R, Attman P-O, Aurell M, Bucht H. Determination of glomerular filtration rate in advanced renal insufficiency. Scand J Urol Nephrol 1978 12: 133-137
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
18. Lacour B, Roullet J-B, Beyne P, Kreis H, Thevenin M, Drüeke T. Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without hemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 1985; 23: 805-810
19. Bergesio F, Monzani G, Ciuti R et al. Lipids and apolipoproteins change during progression of chronic renal failure. Clin Nephrol 38: 264-270
20. Walser M. Progression of chronic renal failure in man. Kidney Int 1990; 37: 1195-1210
21. Striker G. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. J Am Soc Nephrol 1995; 5: 1537-1540
22. Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991; 338: 419-423
23. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-66
24. Modification of Diet in Renal Disease Study Group. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995; 5: 2037-2047
25. Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. J Am Soc Nephrol 1995; 5: 2037-2047
26. Stenvinkel P, Alvestrand A, Bergström J. Factors influencing progression in patients with chronic renal failure. J Intern Med 1989; 226: 183-188
27. Wight JP, Salzano S, Brown CB, El Nahas AM. Natural history of chronic renal failure: a reappraisal. Nephrol Dial Transplant 1992; 7: 379-383
28. Jungers P, Hannedouche T, Itakura Y, Albouze G, Descamps-Latscha B, Man NK. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factos. Nephrol Dial Transplant 1995; 10: 1353-1360
29. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterizations of Apo A- and Apo B-containing lipoprotein families. Prog Lipid Res 1991; 30: 105-138
30. Alaupovic P, Knight-Gibson C, Hodis HN, Mack WJ, Cashin-Hemphill L, Blankenhorn DH. Effect of apoB-containing lipoprotein particles on the progression of atherosclerotic lesions in the Monitored Atherosclerosis Regression Study (MARS). Atherosclerosis 1994; 109: 154
31. Wilens SL, Ester SK, Baker JD. Glomerular lipidosis in intercapillary glomerulosclerosis. Ann Intern Med 1951; 24: 592-607
32. Lee HS, Spargo BH. Significance of renal hyaline arteriosclerosis in focal segmental glomerulosclerosis. Nephron 1985; 41: 86-93
33. Avram MM. Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: a role for lipoprotein glomerulopathy. Am J Med 1987; 87: 39N-41N
34. Lee HS, Lee JS, Koh HI, Koh KW. Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991; 36: 67-75
35. Sato H, Suzuki S, Ueno M et al. Localization of apolipoprotein (a) and B-100 in various renal diseases. Kidney Int 1993; 43: 430-435
36. Takemura T, Yoshioka K, Aya N et al. Apolipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993; 43: 918-927
37. Groene HJ, Walli AK, Groene E, Krämer A, Clemens MR, Seidel D. Receptor mediated uptake of ApoB and ApoE-rich lipoproteins by human glomerular epithelial cells. Kidney Int 1990; 37: 1449-1459
38. Krämer-Guth A, Nauck M, Pavenstädt H et al. Preferential uptake of intermediate density lipoproteins from nephrotic patients by human mesangial and liver cells. J Am Soc Nephrol 1994; 5: 1081-1090
39. Expert Panel. Summmary of the Second Report of the National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 1993; 269: 3015-3023
40. Schaefer EJ. Apolipoproteins and coronary heart disease. Eur J Clin Invest 1994; 24;441-443
41. Hodis HN, Mack WJ, Azen SP et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42-49
42. Hodis HN, Mack WJ, LaBree L et al. Reduction in carotid arterial wall intima-media thickness in a controlled clinical trial of lovastatin and dietary therapy. Ann Intern Med 1996; 124;548-556
43. Slyper AH. A fresh look at the atherogenic remnant hypothesis. Lancet 1992; 340: 289-291
44. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 1990; 81: 470-476
45. Bergström J, Alvestrand A, Bucht H, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25: 1-6
46. Kamper A-L, Standgaard S, Leyssac PP. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995; 10: 1182-1188
47. Burton C, Harris KPG. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996; 27; 765-775
48. Cameron JS. Proteinuria and progression of human glomerular diseases. Am J Nephrol 1990; 10 [Suppl. 1]: 81-87
49. Warwick GL, Fox JG, Boulton-Jones J. The relationship between urinary albumin excretion rate and serum cholesterol in primary glomerular disease. Clin Nephrol 1994; 41: 135-137